Quick Facts: Enalatab's Main Uses

• Supports the management of high blood pressure (hypertension).
• Assists in the treatment of heart failure, often used alongside other medications.
• May be used for individuals with asymptomatic left ventricular dysfunction to help address the condition's progression.

SAFE REWRITE (FULL TEXT)

Enalatab is a medication prescribed to support the management of certain cardiovascular conditions. Its primary use is in the care of high blood pressure, a condition that requires ongoing attention to maintain health. The mechanism of action works to encourage blood vessel relaxation, which helps facilitate the maintenance of a healthy blood pressure level.

The medication is also indicated for the management of symptomatic heart failure when used in combination with appropriate therapeutic agents like diuretics and digitalis. Additionally, it may be utilized in patients who present with asymptomatic left ventricular dysfunction to support cardiac function and reduce associated health risks.

Enalatab (Enalapril maleate) use is governed by specific population eligibility rules defined by government regulatory sources, which outline both permitted groups and mandatory exclusions.

Eligibility Scope

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility by establishing absolute contraindications based on specific medical history (e.g., angioedema) and physiological states (e.g., advanced pregnancy). Eligibility for use is formally established for adults across approved indications and for children ge 1 month for hypertension, while imposing conditional restrictions on populations with organ impairment or those in certain reproductive states.

Interactions with other medicines and products

Enalatab (Enalapril maleate) has documented interaction patterns that influence its systemic effects when co-administered with specific substances, as described in official government prescribing information.

Contraindicated Combinations and Timing Rules

The co-administration of Enalatab with Sacubitril/Valsartan is formally contraindicated due to the risk of angioedema. A mandatory 36-hour washout period is required when initiating Enalatab after discontinuing Sacubitril/Valsartan, or vice-versa.

Pharmacodynamic and Electrolyte Interactions

Co-administration with Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride) or Potassium Supplements carries a documented risk of hyperkalemia due to additive physiological effects. Similarly, the combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the intended antihypertensive effect of Enalatab. The drug is reported to increase serum concentrations of Lithium, potentially leading to toxicity.

Other Exposure and Substance Interactions

Initial use of Enalatab in patients already receiving Diuretic Therapy may result in excessive hypotension. The risk of haematological disorders is increased when used concurrently with agents like Allopurinol or Immunosuppressants. Official labeling notes that alcohol enhances the antihypertensive effect but confirms that the extent of absorption is not affected by food.

Enalatab functions as a targeted inhibitor of the enzyme Cathepsin K. This cysteine protease is predominantly expressed by osteoclasts, the cells responsible for bone resorption. Enalatab achieves inhibition of Cathepsin K activity by selectively binding to the enzyme's active site . This molecular interaction blocks the catalytic function of Cathepsin K. Consequently, the drug reduces the enzymatic degradation of Type I collagen, which constitutes the major organic matrix of bone tissue. By modulating this key molecular step, Enalatab influences the overall biochemical pathway involving osteoclast-mediated bone resorption, leading to a sustained alteration in the progression of the Cathepsin K-dependent cellular process within the skeletal system.

Official Administration Guidelines for Enalatab

Enalatab is used through oral administration in the form of a tablet, and the medicine can be taken consistently, with or without food, for patient convenience. The core principle of administration is a controlled, gradual adjustment process known as titration.

Treatment is typically initiated at a low dose to assess initial response, often starting at 5 mg once daily for managing hypertension, or an even lower dose, such as 2.5 mg, when initiating treatment for heart failure.

Dosing Patterns and Adjustments

Enalatab is designed for long-term, chronic management of cardiovascular conditions. Dose adjustment is a mandatory procedural step for specific populations. Patients with impaired renal function generally require a lower starting dose, such as 2.5 mg, to align with the altered clearance rate. If a scheduled dose is missed, it should generally be skipped if the next dose is due soon, and a double dose must not be taken to compensate.

Research evidence / Overview of studies for Enalatab

Evidence for use in High Blood Pressure (Hypertension)

Research examining Enalatab's use for high blood pressure was conducted primarily through Randomized Controlled Trials (RCTs). These studies typically explored short-term changes, measuring outcomes related to systolic and diastolic blood pressure in individuals. Studies monitored changes in blood pressure measurements, and the data reported differences compared to the control group during the study periods. However, evidence is limited regarding long-term prospective RCT data characterizing cardiovascular outcomes, as much of the initial definitive research focused on short-term blood pressure measurements.

Evidence for use in Symptomatic Heart Failure

The evidence for Enalatab in symptomatic heart failure (specifically with reduced ejection fraction) is derived from large-scale, long-term, multinational Randomized Controlled Trials. These studies were structured to evaluate critical long-term outcomes, including patient survival (all-cause mortality) and the frequency of hospitalization due to heart failure exacerbations. Research reported data showing patterns related to all-cause mortality and heart failure-related hospitalizations when compared to the control group. However, the evidence from these landmark trials is mainly focused on patients with moderate-to-severe heart failure, meaning the evidence for individuals with very mild or early-stage symptomatic heart failure is less characterized.

Evidence for use in Asymptomatic Left Ventricular Dysfunction

Research examined the use of Enalatab in patients who have left ventricular dysfunction but do not yet have symptoms of heart failure. Large-scale trials monitored these adults over several years, focusing on the progression of the condition. Research described data showing patterns related to the rate of progression to symptomatic heart failure and related hospitalizations when compared to the placebo group. However, the evidence for distinct findings related to all-cause mortality in this specific asymptomatic population remains limited.

What is Still Uncertain About the Research Evidence

One area of uncertainty is the long-term comparative evidence between Enalatab and newer classes of cardiovascular medications. Additionally, the role of Enalatab in Heart Failure with Preserved Ejection Fraction (HFpEF) lacks consistency in its findings regarding functional measures. Across multiple indications, the data for certain groups remain insufficient, particularly for very young children and certain complex comorbidity groups, meaning research provides context but not individual predictions for all patients.

Common questions about Enalatab (FAQ)

Q: What is Enalatab indicated to treat?

A: Enalatab is indicated for the management of chronic conditions, specifically conditions X and Y, as approved by regulatory bodies.

Q: How does Enalatab function in the body?

A: Enalatab is classified as a specific class of pharmacological agent. It primarily influences a certain type of cellular receptor, which may help to mediate the therapeutic effects observed in clinical studies for its indicated uses.

Q: When might a person begin to observe the effects of Enalatab?

A: Clinical trial data suggests that individuals may experience the therapeutic effects of Enalatab within a specific timeframe after initiating treatment. However, the time required to observe a noticeable change can vary among patients.

Q: Are there any known common or serious side effects associated with Enalatab?

A: Clinical trials have identified several commonly occurring side effects, which may include mild headache, fatigue, or temporary gastrointestinal discomfort. Reports of serious adverse events are rare, but patients should consult their healthcare provider if they experience any concerning symptoms while taking this medication. Patient-specific risk factors should always be considered.

Q: Can Enalatab be taken alongside other medications?

A: It is essential for a patient to inform their healthcare provider of all current medications, including prescription and over-the-counter drugs, as potential interactions with Enalatab have been documented. The provider can then assess the safety of the specific medication combination.

How to Store and Dispose of Enalatab (Enalapril Maleate)

Enalapril maleate tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be kept in the original container, which must be tightly closed, and stored away from both moisture and direct light.

Crucially, all forms of enalapril must not be frozen and must be kept out of the reach and sight of children. If utilizing the oral solution, it must be discarded if not used within 60 days of being prepared.

For disposal, unused or expired Enalatab should be handled according to local regulations. The official guidance recommends using a drug take-back program rather than discarding the product in the household trash or flushing it.